Sign Up Today and Learn More About Seaport Therapeutics Stock
Invest in or calculate the value of your shares in Seaport Therapeutics or other pre-IPO companies through EquityZen's platform.
Seaport Therapeutics Stock (SEPT)
Seaport Therapeutics operates as a clinical stage biopharmaceutical company.
About Seaport Therapeutics Stock
Founded
2024
Headquarters
Boston, MA, US
Industries
Software, Artificial Intelligence, Data and Analytics
Seaport Therapeutics Press Mentions
Stay in the know about the latest news on Seaport Therapeutics
ARPA-H launches $158M effort to aid first-ever lymphatic system medicines
fiercebiotech • Mar 10, 2026
Seaport Therapeutics and Monash Institute of Pharmaceutic...
pharmiweb • Mar 04, 2026
Seaport Therapeutics Presents New Meta-Analysis Examining the Impact of Clinical Trial Design Factors on Placebo Response in Generalized Anxiety Disorder Trials
biospace • Feb 20, 2026
Seaport Therapeutics Presents New Meta-Analysis Examining the Impact of Clinical Trial Design Factors on Placebo Response in Generalized Anxiety Disorder Trials
businesswire • Feb 20, 2026
Seaport Therapeutics Presents New Meta-Analysis Examining...
pharmiweb • Feb 20, 2026
Seaport Therapeutics Management
Leadership team at Seaport Therapeutics
Chief Medical Officer and President of Clinical Development
Antony Loebel
Board of Director
James Healy
Join now and verify your accreditation status to gain access to:
- Seaport Therapeutics Current Valuation
- Seaport Therapeutics Stock Price
- Seaport Therapeutics Management
- Available deals in Seaport Therapeutics and all other companies with relevant Deal Offering documents
- EquityZen's proprietary data and insights, which may include
- Seaport Therapeutics Cap Table and Funding History by Share Class and Liquidity Preferences
- Seaport Therapeutics Revenue and Financials
- Seaport Therapeutics Highlights
- Seaport Therapeutics Business Model
- Seaport Therapeutics Risk Factors
- Seaport Therapeutics Research Report from SACRA Research
Trading Seaport Therapeutics Stock
How to invest in Seaport Therapeutics stock?
Accredited investors can buy pre-IPO stock in companies like Seaport Therapeutics through EquityZen funds. These investments are made available by existing Seaport Therapeutics shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process for buying Pre-IPO Shares.
How to sell Seaport Therapeutics stock?
Shareholders can sell their Seaport Therapeutics stock through EquityZen's private company marketplace. EquityZen's network includes over 430K accredited investors interested in buying private company stock. Learn more about the Shareholder liquidity process.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. See more information on Express Deals and pre-IPO exit information.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 52K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."
